Nrx Pharmaceuticals Inc (NRXP) Stock Price, Quote & News

Latest News on NRXP

Jan 15, 2025, 8:02 AM EST - 2 days ago

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces the Appointment of Michael Taylor to its Board of Directors and Appointment of Anita Nunes as Board Observer; Ms. Nunes to be Appointed Director of HOPE Therapeutics, Inc.

Jan 14, 2025, 8:03 AM EST - 3 days ago

HOPE Therapeutics™, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Alert Investors to Sanjay Gupta/CNN Program on Ketamine, Featuring Kadima Neuropsychiatry Institute Founder Dr. David Feifel

Jan 13, 2025, 8:04 AM EST - 4 days ago

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces it has Filed an Application with NASDAQ to Uplist to the NASDAQ Global Market from the NASDAQ Capital Market

Jan 8, 2025, 10:20 AM EST - 9 days ago

Central Nervous System (CNS) Therapeutics Market Forecast (2025-2035) by Disease, Drug Class, Distribution Channel and Region

Jan 7, 2025, 8:07 AM EST - 10 days ago

HOPE Therapeutics™, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Dr. Jonathan Javitt and Dr. David Feifel to Present Keynote Address, Beyond Ketamine Monotherapy: Combined Interventional Treatment of Suicidal Depression and PTSD, at the 8th Annual Neuroscience Innovation Forum in San Francisco

Jan 6, 2025, 10:16 AM EST - 11 days ago

HOPE Therapeutics™, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Signing of Binding Term Sheet for $27 Million in Funding for HOPE Clinic Acquisitions and Pharmaceutical Operations

Jan 6, 2025, 8:03 AM EST - 11 days ago

HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Announce Dura Medical as the Expected Initial Florida Acquisition for its Planned International Network of Interventional Psychiatry Clinics

Jan 2, 2025, 8:03 AM EST - 15 days ago

Hope Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Kadima Neuropsychiatry Institute as the Expected First Acquisition for its International Network of Interventional Psychiatry Clinics

Dec 30, 2024, 8:03 AM EST - 18 days ago

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Files Initial Section of U.S. New Drug Application to the FDA for NRX-100 (IV Ketamine) for the Treatment of Suicidal Depression

Nov 26, 2024, 8:03 AM EST - 7 weeks ago

NRx Pharmaceuticals (NASDAQ: NRXP) Announces Participation in the NobleCon20 - Noble Capital Markets' Twentieth Annual Emerging Growth Equity Conference December 3-4, 2024

Nov 25, 2024, 8:03 AM EST - 7 weeks ago

NRx Pharmaceuticals (NASDAQ:NRXP) Announces Publication of Paper Entitled "Quality Assurance of Depression Ratings in Psychiatric Clinical Trials"

Nov 18, 2024, 7:51 PM EST - 2 months ago

NRx Pharmaceuticals, Inc. (NRXP) Q3 2024 Earnings Call Transcript

Nov 18, 2024, 4:05 PM EST - 2 months ago

NRx Pharmaceuticals (NASDAQ:NRXP) Appoints Michael Abrams as Chief Financial Officer

Nov 14, 2024, 4:05 PM EST - 2 months ago

NRx Pharmaceuticals (NASDAQ:NRXP) Reports Third Quarter and Year to Date 2024 Financial Results and Provides Business Update

Nov 13, 2024, 8:03 AM EST - 2 months ago

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reschedules Conference Call to Discuss Third Quarter and Year to Date 2024 Financial Results to November 18, 2024

Nov 7, 2024, 4:06 PM EST - 2 months ago

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report Third Quarter and Year to Date 2024 Financial Results on November 14, 2024

Oct 30, 2024, 7:47 AM EDT - 2 months ago

HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) Announce Signing of a Letter of Intent to Acquire its First Florida Interventional Psychiatry Clinics

Oct 3, 2024, 6:55 AM EDT - 3 months ago

HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) Announce Signing of a Letter of Intent to Acquire a Premier West Coast Interventional Psychiatric Clinic

Sep 30, 2024, 7:00 AM EDT - 3 months ago

NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) Announces Completion of Twelve Months of Stability on the First Manufactured Commercial Scale Lot of NRX-100 (Ketamine)

Sep 11, 2024, 7:55 AM EDT - 4 months ago

NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) Featured on Psychiatrist.com

Sep 3, 2024, 7:55 AM EDT - 4 months ago

NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) and HOPE Therapeutics, Inc. Announce Participation at the H.C. Wainwright 26th Annual Global Investment Conference September 9-11, 2024

Aug 26, 2024, 7:55 AM EDT - 5 months ago

HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) Announce Potential Acquisition and Financing Agreements for $30 Million in Currently-Operating Interventional Psychiatry Clinics

Aug 15, 2024, 2:39 PM EDT - 5 months ago

NRx Pharmaceuticals, Inc. (NRXP) Q2 2024 Earnings Call Transcript

Aug 14, 2024, 4:01 PM EDT - 5 months ago

NRx Pharmaceuticals (NASDAQ:NRXP) Reports Second Quarter and Year to Date 2024 Financial Results and Provides Business Update

Aug 13, 2024, 4:01 PM EDT - 5 months ago

NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) to Report Second Quarter and Year to Date 2024 Financial Results on August 14, 2024

Aug 13, 2024, 7:30 AM EDT - 5 months ago

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces Up to $16 Million Senior Secured Debt Financing from Anson Funds

Jul 29, 2024, 8:35 AM EDT - 6 months ago

HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) Announce Alignment with FDA on Pediatric Study Plan for NRX-100 (ketamine)

Jul 29, 2024, 8:30 AM EDT - 6 months ago

HOPE Therapeutics, Inc. and NRx Pharmaceuticals (Nasdaq:NRXP) Announce Arbitration Order Enabling HOPE Therapeutics Spinoff

Jul 1, 2024, 8:07 AM EDT - 7 months ago

NRx Pharmaceuticals (NASDAQ:NRXP) Publishes Shareholder Update Letter

Jun 28, 2024, 8:07 AM EDT - 7 months ago

NRx Pharmaceuticals (NASDAQ:NRXP) to Proceed with Two New Drug Applications in 2024; NRX-101 has Been Returned to the Company for Filing

Jun 20, 2024, 8:30 AM EDT - 7 months ago

NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference on June 27, 2024

Jun 18, 2024, 8:30 AM EDT - 7 months ago

NRx Pharmaceuticals (NASDAQ:NRXP) Appoints Neuroscience, Information Technology and Medical Technology Veteran to its Board of Directors

May 28, 2024, 8:30 AM EDT - 8 months ago

NRx Pharmaceuticals (Nasdaq:NRXP) Presents Landmark Trial of NRX-101 in Suicidal Bipolar Depression At the American Society of Clinical Psychopharmacology Annual Meeting: NRX-101 is the First Oral Antidepressant Demonstrated to Reduce Suicidality in Bipol

May 14, 2024, 8:11 PM EDT - 8 months ago

NRx Pharmaceuticals, Inc. (NRXP) Q1 2024 Earnings Call Transcript

May 14, 2024, 4:01 PM EDT - 8 months ago

NRx Pharmaceuticals (Nasdaq:NRXP) Reports First Quarter 2024 Financial Results and Provides Business Update

May 8, 2024, 8:30 AM EDT - 9 months ago

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Participate in the EF Hutton Annual Global Conference on May 15, 2024

May 7, 2024, 4:01 PM EDT - 9 months ago

NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) to Report First Quarter 2024 Financial Results on May 14, 2024

May 6, 2024, 8:30 AM EDT - 9 months ago

NRx Pharmaceuticals (Nasdaq:NRXP) Announces Final Clinical Trial Results: Superior Safety Combined with Similar Efficacy in the Trial of NRX-101 Compared to Lurasidone in Suicidal Bipolar Depression

Apr 30, 2024, 8:30 AM EDT - 9 months ago

NRx Pharmaceuticals (Nasdaq:NRXP) Announces Promising Findings in Phase 2b/3 Clinical Trial of NRX-101 vs. Lurasidone for Treatment of Suicidal Bipolar Depression

Apr 18, 2024, 8:32 AM EDT - 9 months ago

NRx Pharmaceuticals (NASDAQ:NRXP) Receives Notice from Nasdaq that the Company has Demonstrated Compliance with the Bid Price Requirement

Apr 18, 2024, 8:30 AM EDT - 9 months ago

NRx Pharmaceuticals, Inc. Announces Pricing of $2.0 Million Underwritten Public Offering of Common Stock

Apr 17, 2024, 4:45 PM EDT - 9 months ago

NRx Pharmaceuticals, Inc. Announces Proposed Underwritten Public Offering of Common Stock

Apr 15, 2024, 8:30 AM EDT - 9 months ago

NRx Pharmaceuticals (NASDAQ:NRXP) Announces Development of New, Proprietary Formulation of HTX-100 (IV Ketamine)

Apr 8, 2024, 8:30 AM EDT - 10 months ago

NRx Pharmaceuticals (NASDAQ:NRXP) Announces Data-Lock of Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression

Apr 1, 2024, 3:08 PM EDT - 10 months ago

NRX Pharmaceuticals, Inc. (NRXP) Q4 2023 Earnings Call Transcript

Apr 1, 2024, 8:28 AM EDT - 10 months ago

NRx Pharmaceuticals (Nasdaq:NRXP) Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Mar 28, 2024, 8:03 AM EDT - 10 months ago

NRx Pharmaceuticals (NASDAQ:NRXP) Reports Preliminary Fourth Quarter and Full Year 2023 Financial Results and Provides Year End Highlights

Mar 28, 2024, 8:00 AM EDT - 10 months ago

NRx Pharmaceuticals Announces Reverse Stock Split to Maintain Nasdaq Listing

Mar 26, 2024, 4:03 PM EDT - 10 months ago

UPDATE: NRx Pharmaceuticals (NASDAQ: NRXP) to Report Fourth Quarter and Full Year 2023 Financial Results on March 28, 2024

Mar 25, 2024, 8:30 AM EDT - 10 months ago

Market Cap	51.52M
Revenue (ttm)	0.00
Net Income (ttm)	-30.15M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	-0.19

Volume	1,065,600
Avg Vol	1,241,136
Day's Range	N/A - N/A
Shares Out	12.09M
Stochastic %K	49%
Beta	1.08
Analysts	Strong Sell
Price Target	$31.67